genprowebdirectory
Skip to content
Facebook
LinkedIn
RSS
Twitter/X
YouTube
GEN Edge
Featured News
Multimedia
Content
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits & Spotlights
Webinars
GEN Live
Learning Labs
Podcasts
Videos
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Toggle Search
Search for:
Search
Search
Toggle Mobile Menu
Toggle Search
×
GEN Edge
Expand submenu
Featured News
Multimedia
Content
Expand submenu
News
Insights
Topics
Expand submenu
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Expand submenu
Browse Issues
Subscribe
Multimedia
Expand submenu
Summits & Spotlights
Webinars
GEN Live
Learning Labs
Podcasts
Videos
Resources
Expand submenu
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
Expand submenu
GEN Biotechnology
Re:Gen Open
New Products
Subscribe
Expand submenu
Get GEN Magazine
Get GEN eNewsletters
×
Search for:
Search
Search
Home
>
Multimedia
>
Podcasts
>
IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES
IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES
June 19, 2008
– Interview with Sharon Terry, President and CEO of the Genetic Alliance
/wp-content/uploads/2018/09/gc215_6_19_2008.mp3
Podcasts
Resources
Clinical laboratory technique
Diagnosis
Diagnostic techniques
Genetic testing (Diagnostic technique)
Medicine, Diagnosis, and Therapeutics
Molecular technique
Also of Interest
FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates
Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
Advancing Cell Therapy for Cardiovascular Disease
StockWatch: Novo's 2030 Strategy Underwhelms Investors at Capital Markets Day
Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders
The Next Frontier in Bioprocessing: Quality by Understanding
Related Media
Data Integrity as the Foundation for AI
AI in Protein Design: Hype vs. Reality Explained by David Baker
Emerging Markets Collaborate to Succeed in Post-Pandemic World
Breathing Oxygen Back into the Biological Conversation
Global Single-Use Network Support Assurance of Supply
Resins Address Downstream Purification Concerns
